# Solu Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/solu-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.solutherapeutics.com
- Total disclosed funding: $56M
- Latest round: Series A (Apr 9, 2025)
- Investors on record: 10

## About

Founded in 2023 by David Donabedian and Brandon Turunen, and based in Massachusetts, US, Solu Therapeutics, Inc. operates as a precision medical technology company that develops precision medicine for the elimination of cells causing various diseases. In April 2025, Solu Therapeutics, Inc. raised USD 41 million in series A funding from new investors Eli Lilly & Company, Biovision Ventures, Pappas Capital, Pappas Capital, and The Leukemia & Lymphoma Society. Returning investors Longwood Fund, Data Collective, Sante Ventures, Astellas Venture Management, and Alexandria Venture Investments also participated in the round. The company uses its proprietary CyTaC platform to create therapies to help treat and eliminate disease-causing cells that cause diseases such as cancer, immunology, and autoimmunity. The company enables the development of next-generation medicines that combine the power of biologics with the vast target binding space of small molecules by unlocking antibody-intractable cell surface targets. The company plans to utilize the April 2025 funding to expand the pipeline, investigate new uses for the CyTAC and TicTAC platforms, launch new discovery programs that target harmful cells, complete dose escalation, and create new development candidates, such as a first-of-its-kind mast cell depletor for immunological disorders.

## Funding rounds

- Series A, Apr 9, 2025, $40M — Lilly Ventures, Pappas Capital, Alexandria Venture Investments, Astellas Venture Management, Sante Ventures, Longwood Fund, The Leukemia & Lymphoma Society, DCVC, Hengdian Group, Biovision Ventures
- Seed, May 15, 2023, $16M — Alexandria Venture Investments, Astellas Venture Management, Sante Ventures, Longwood Fund, DCVC

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed, Series A
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Seed, Series A
- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Seed, Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Seed, Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- The Leukemia & Lymphoma Society — Series A
- Hengdian Group — Series A
- Biovision Ventures (https://capitalatlas.ai/funds/biovision-ventures) — Series A